Pan Asia Metals Limited

PAM

Pan Asia Metals Ltd. engages in the identification, exploration, development, and operation of metal properties. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2020-10-08. The principal activities of its subsidiaries are in the identification and development of specialty metals assets situated in low-cost environments which are proximal to advanced industrial centers. The company has lithium projects in South-East Asia and South America, and agreements with key battery and chemical producers in the Asian region to produce advanced battery chemicals. The Reung Kiet Lithium Project is a lepidolite-style lithium project located about 70 kilometers (km) northeast of Phuket in the Phang Nga Province in southern Thailand. The Tama Atacama Lithium Project is a series of brine and clay lithium holdings located in the Atacama Desert in Northern Chile. The Kata Thong Geothermal Lithium & Hard Rock Lithium-Tin Project is a compilation of five Special Prospecting License Applications in the Phang Nga Province in southern Thailand covering approximately 45 square kilometers.

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is engaged in discovering, developing, and delivering pharmaceutical therapies. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).

Patrys Limited

PAB

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). The company has developed two humanized forms of deoxymab 3E10, both have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown an ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. This allows specific delivery of cancer drugs to multiple types of cancer.

Pacific Current Group Limited

PAC

Pacific Current Group Ltd. engages in the business of investing in asset managers, private advisory, placement, and investment related firms. The company is headquartered in Sydney, New South Wales and currently employs 7 full-time employees. The firm is engaged in investing in asset managers, private advisory, placement and investment-related firms on a global basis. The firm operates a portfolio of 15 specialist boutiques in Australia, India, Luxembourg, the United States, and the United Kingdom. The Company’s portfolio represents an array of strategies, diversified across investment strategy, geography, revenue model, and client type. Its portfolio of companies includes Aether Investment Partners, LLC, Astarte Capital Partners, LLP, Carlisle Management Company, S.C.A., Cordillera Investment Partners, LP, Victory Park Capital Advisors, LLC and others. Aether Investment Partners, LLC is focused on private investments in natural resources, infrastructure and opportunistic real assets. Astarte Capital Partners, LLP is focused on infrastructure, natural resources, transportation, and real estate.